<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BEXTRA- valdecoxib tablet, film coated </strong><br>G.D. Searle LLC<br></p></div>
<h1>BEXTRA<span class="Sup">®</span><br>valdecoxib tablets</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Boxed"></a><a name="section-2.1"></a><p></p>
<h2>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First"></p>
<ul>
<li><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>) have been reported in patients receiving BEXTRA.  Some of these reactions have resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></li>
<li><span class="Bold">Patients appear to be at higher risk for these events within the first 2 weeks of treatment, but these may occur at any time during treatment. </span></li>
<li><span class="Bold"> The reported rate of these serious skin events appears to be greater for BEXTRA as compared to other COX-2 agents.</span></li>
<li><span class="Bold">BEXTRA should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, mucosal lesions, or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</span></li>
</ul>
<p><span class="Bold">(See <a href="#Serious_Skin_Reactions">WARNINGS – Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>)</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Valdecoxib is chemically designated as 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide and is a diaryl substituted isoxazole.  It has the following chemical structure:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=CAF64301-262C-45CA-ACD1-A9D6696C584E&amp;name=bextra-image01.jpg"></div>
<p>  The empirical formula for valdecoxib is C<span class="Sub">16</span>H<span class="Sub">14</span>N<span class="Sub">2</span>O<span class="Sub">3</span>S, and the molecular weight is 314.36.  Valdecoxib is a white crystalline powder that is relatively insoluble in water (10 µg/mL) at 25°C and pH 7.0, soluble in methanol and ethanol, and freely soluble in organic solvents and alkaline (pH=12) aqueous solutions.</p>
<p>BEXTRA Tablets for oral administration contain either 10 mg or 20 mg of valdecoxib. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, magnesium stearate, hypromellose, polyethylene glycol, polysorbate 80, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic and antipyretic properties in animal models. The mechanism of action is believed to be due to inhibition of prostaglandin synthesis primarily through inhibition of cyclooxygenase-2 (COX-2).  At therapeutic plasma concentrations in humans valdecoxib does not inhibit cyclooxygenase-1 (COX-1).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Valdecoxib achieves maximal plasma concentrations in approximately 3 hours.  The absolute bioavailability of valdecoxib is 83% following oral administration of BEXTRA compared to intravenous infusion of valdecoxib.</p>
<p>Dose proportionality was demonstrated after single doses (1–400 mg) of valdecoxib.  With multiple doses (up to 100 mg/day for 14 days), valdecoxib exposure as measured by the AUC, increases in a more than proportional manner at doses above 10 mg BID.  Steady state plasma concentrations of valdecoxib are achieved by day 4.</p>
<p>The steady state pharmacokinetic parameters of valdecoxib in healthy male subjects are shown in Table 1.</p>
<table width="50%">
<caption><span>Table 1  Mean (SD) Steady State Pharmacokinetic Parameters</span></caption>
<col align="left" width="65%">
<col align="center" width="35%">
<thead><tr class="First Last">
<th class="Lrule" align="left">Steady State Pharmacokinetic Parameters after Valdecoxib 10 mg Once Daily for 14 Days</th>
<th class="Lrule Rrule" align="center" valign="bottom">Healthy Male Subjects<br>(n=8, 20 to 42 yr.)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">AUC<span class="Sub">(0–24hr) </span>(hr∙ng/mL)</td>
<td class="Botrule Lrule Rrule" align="center">1479.0 (291.9)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">C<span class="Sub">max </span>(ng/mL)</td>
<td class="Botrule Lrule Rrule" align="center">161.1  (48.1)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">T<span class="Sub">max</span> (hr)</td>
<td class="Botrule Lrule Rrule" align="center">2.25  (0.71)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">C<span class="Sub">min</span> (ng/mL)</td>
<td class="Botrule Lrule Rrule" align="center">21.9  (7.68)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Elimination Half-life (hr)</td>
<td class="Lrule Rrule" align="center">8.11  (1.32)</td>
</tr>
</tbody>
</table>
<p>    No clinically significant age or gender differences were seen in pharmacokinetic parameters that would require dosage adjustments.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.2"></a><p></p>
<h3>Effect of Food and Antacid</h3>
<p class="First">BEXTRA can be taken with or without food.  Food had no significant effect on either the peak plasma concentration (C<span class="Sub">max</span>) or extent of absorption (AUC) of valdecoxib when BEXTRA was taken with a high fat meal.  The time to peak plasma concentration (T<span class="Sub">max)</span>, however, was delayed by 1–2 hours.  Administration of BEXTRA with antacid (aluminum/magnesium hydroxide) had no significant effect on either the rate or extent of absorption of valdecoxib.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.3"></a><p></p>
<h3>Distribution</h3>
<p class="First">    Plasma protein binding for valdecoxib is about 98% over the concentration range (21–2384 ng/mL). Steady state apparent volume of distribution (Vss/F) of valdecoxib is approximately 86 L after oral administration.  Valdecoxib and its active metabolite preferentially partition into erythrocytes with a blood to plasma concentration ratio of about 2.5:1.  This ratio remains approximately constant with time and therapeutic blood concentrations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.4"></a><p></p>
<h3>Metabolism</h3>
<p class="First">In humans, valdecoxib undergoes extensive hepatic metabolism involving both P450 isoenzymes (3A4 and 2C9) and non-P450 dependent pathways (i.e., glucuronidation).  Concomitant administration of BEXTRA with known CYP 3A4 and 2C9 inhibitors (e.g., fluconazole and ketoconazole) can result in increased plasma exposure of valdecoxib (see <a href="#Drug_Interactions">PRECAUTIONS — Drug Interactions</a>).</p>
<p>One active metabolite of valdecoxib has been identified in human plasma at approximately 10% the concentration of valdecoxib.  This metabolite, which is a less potent COX-2 specific inhibitor than the parent, also undergoes extensive metabolism and constitutes less than 2% of the valdecoxib dose excreted in the urine and feces.  Due to its low concentration in the systemic circulation, it is not likely to contribute significantly to the efficacy profile of BEXTRA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.5"></a><p></p>
<h3>Excretion</h3>
<p class="First">Valdecoxib is eliminated predominantly via hepatic metabolism with less than 5% of the dose excreted unchanged in the urine and feces.  About 70% of the dose is excreted in the urine as metabolites, and about 20% as valdecoxib N-glucuronide.  The apparent oral clearance (CL/F) of valdecoxib is about 6 L/hr. The mean elimination half-life (T<span class="Sub">1/2)</span> ranges from 8–11 hours, and increases with age.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Special Populations</h2>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.1"></a><p></p>
<h3>Geriatric</h3>
<p class="First">In elderly subjects (&gt; 65 years), weight-adjusted steady state plasma concentrations (AUC<span class="Sub">(0–12hr)</span>) are about 30% higher than in young subjects.  No dose adjustment is needed based on age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.2"></a><p></p>
<h3>Pediatric</h3>
<p class="First">BEXTRA has not been investigated in pediatric patients below 18 years of age.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.3"></a><p></p>
<h3>Race</h3>
<p class="First">Pharmacokinetic differences due to race have not been identified in clinical and pharmacokinetic studies conducted to date.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h3>
<p class="First">Valdecoxib plasma concentrations are significantly increased (130%) in patients with moderate (Child-Pugh Class B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In clinical trials, doses of BEXTRA above those recommended have been associated with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.  Hence, treatment with BEXTRA should be initiated with caution in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.  The use of BEXTRA in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C) is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h3>
<p class="First">The pharmacokinetics of valdecoxib have been studied in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Because renal elimination of valdecoxib is not important to its disposition, no clinically significant changes in valdecoxib clearance were found even in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or in patients undergoing renal dialysis. In patients undergoing hemodialysis the plasma clearance (CL/F) of valdecoxib was similar to the CL/F found in healthy elderly subjects (CL/F about 6 to 7 L/hr.) with normal renal function (based on creatinine clearance).</p>
<p>NSAIDs have been associated with worsening renal function and use in advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> is not recommended (see <a href="#Renal_Effects">PRECAUTIONS — Renal Effects</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">For quantitative information on the following drug interaction studies, see <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS — Drug Interactions</a></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.4.1"></a><p></p>
<h3>General</h3>
<p class="First">Valdecoxib undergoes both P450 (CYP) dependent and non-P450 dependent (glucuronidation) metabolism. In vitro studies indicate that valdecoxib is not a significant inhibitor of CYP 1A2, 3A4, or 2D6 and is a weak inhibitor of CYP 2C9 and a weak to moderate inhibitor of CYP 2C19 at therapeutic concentrations.  The P450-mediated metabolic pathway of valdecoxib predominantly involves the 3A4 and 2C9 isozymes.  Using prototype inhibitors and substrates of these isozymes, the following results were obtained. Coadministration of a known inhibitor of CYP 2C9/3A4 (fluconazole) and a CYP 3A4 inhibitor (ketoconazole) enhanced the total plasma exposure (AUC) of valdecoxib. Coadministration of valdecoxib with a CYP 3A4 inducer (phenytoin) decreased total plasma exposure (AUC) of valdecoxib. (See <a href="#Drug_Interactions">PRECAUTIONS — Drug Interactions</a>.) </p>
<p>Coadministration of valdecoxib with warfarin (a CYP 2C9 substrate) caused a small, but statistically significant increase in plasma exposures of R-warfarin and S-warfarin, and also in the pharmacodynamic effects (International Normalized Ratio-INR) of warfarin. (See <a href="#Drug_Interactions">PRECAUTIONS — Drug Interactions</a>.)</p>
<p>Coadministration of valdecoxib with diazepam (a CYP 2C19/3A4 substrate) resulted in increased exposure of diazepam, but not its major metabolite, desmethyldiazepam. (See <a href="#Drug_Interactions">PRECAUTIONS — Drug Interactions</a>.)</p>
<p>Coadministration of valdecoxib with glyburide (a CYP 2C9 substrate) (40 mg valdecoxib QD with 10 mg glyburide BID) resulted in increased exposure of glyburide. (See<a href="#Drug_Interactions"> PRECAUTIONS — Drug Interactions</a>.)</p>
<p>Coadministration of valdecoxib with an oral contraceptive, 1 mg norethindrone/0.035 mg ethinyl estradiol (CYP 3A4 substrates), resulted in increased exposure of both norethindrone and ethinyl estradiol. (See <a href="#Drug_Interactions">PRECAUTIONS — Drug Interactions</a>.)</p>
<p>Coadministration of valdecoxib with omeprazole (a CYP 3A4/2C19 substrate) caused an increase in omeprazole exposure.  (See <a href="#Drug_Interactions">PRECAUTIONS — Drug Interactions</a>.)</p>
<p>Coadministration of valdecoxib with dextromethorphan (a CYP 2D6/3A4 substrate) resulted in an increase in dextromethorphan plasma levels above those seen in subjects with normal levels of CYP 2D6.  Even so these levels were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers.  (See <a href="#Drug_Interactions">PRECAUTIONS — Drug Interactions</a>.)</p>
<p>Coadministration of valdecoxib with phenytoin (a CYP 2C9/2C19 substrate) did not affect the pharmacokinetics of phenytoin.</p>
<p>Coadministration of valdecoxib, or its injectable prodrug, with substrates of CYP 2C9 (propofol) and CYP 3A4 (midazolam, alfentanil, fentanyl) did not inhibit the metabolism of these substrates.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">The efficacy and clinical utility of BEXTRA Tablets have been demonstrated in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> (OA), <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (RA) and in the treatment of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">primary dysmenorrhea</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span></h2>
<p class="First">BEXTRA was evaluated for treatment of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> of the knee or hip, in five double-blind, randomized, controlled trials in which 3918 patients were treated for 3 to 6 months.  BEXTRA was shown to be superior to placebo in improvement in three domains of OA symptoms: (1) the WOMAC (Western Ontario and McMaster Universities) <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> index, a composite of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span> and functional measures in OA, (2) the overall patient assessment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and (3) the overall patient global assessment. The two 3-month pivotal trials in OA generally showed changes statistically significantly different from placebo, and comparable to the naproxen control, in measures of these domains for the 10 mg/day dose.  No additional benefit was seen with a valdecoxib 20-mg daily dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First">BEXTRA demonstrated significant reduction compared to placebo in the signs and symptoms of RA, as measured by the ACR (American College of Rheumatology) 20 improvement, a composite defined as both improvement of 20% in the number of tender and number of <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">swollen joints</span>, and a 20% improvement in three of the following five: patient global, physician global, patient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, patient function assessment, and C-reactive protein (CRP).  BEXTRA was evaluated for treatment of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> in four double-blind, randomized, controlled studies in which 3444 patients were treated for 3 to 6 months.  The two 3-month pivotal trials compared valdecoxib to naproxen and placebo.  The results for the ACR20 responses in these trials are shown below (Table 2).  Trials of BEXTRA in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> allowed concomitant use of corticosteroids and/or disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, gold salts, and hydroxychloroquine.  No additional benefit was seen with a valdecoxib 20-mg daily dose.</p>
<table width="50%">
<caption><span>Table 2 ACR20 Response Rate (%) in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></span></caption>
<col align="left" width="34%">
<col align="center" width="33%">
<col align="center" width="33%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center">Study 1</th>
<th class="Lrule Rrule" align="center">Study 2</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>p&lt; 0.001 compared to placebo</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>p&lt;0.01; </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">BEXTRA 10 mg/day</td>
<td class="Botrule Lrule" align="center">49%<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> (103/209)</td>
<td class="Botrule Lrule Rrule" align="center">46%<a href="#footnote-1" class="Sup">*</a> (103/226)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">BEXTRA 20 mg/day</td>
<td class="Botrule Lrule" align="center">48%<a href="#footnote-1" class="Sup">*</a>  (102/212)</td>
<td class="Botrule Lrule Rrule" align="center">47%<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> (103/219)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Naproxen 500 mg BID</td>
<td class="Botrule Lrule" align="center">44%<a href="#footnote-2" class="Sup">†</a> 	(100/225)</td>
<td class="Botrule Lrule Rrule" align="center">53%<a href="#footnote-1" class="Sup">*</a>  (115/219)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">Placebo</td>
<td class="Lrule" align="center">32% (70/222)</td>
<td class="Lrule Rrule" align="center">32% (71/220)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Primary Dysmenorrhea</span></h2>
<p class="First">BEXTRA was compared to naproxen sodium 550 mg in two placebo-controlled studies of women with moderate to severe <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">primary dysmenorrhea</span>.  The onset of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> was within 60 minutes for BEXTRA 20 mg. The onset, magnitude, and duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> with BEXTRA 20 mg were comparable to naproxen sodium 550 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Safety_Studies"></a><a name="section-4.4"></a><p></p>
<h2>Safety Studies</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.1"></a><p></p>
<h3>Studies in post-surgical patients (Investigational use)</h3>
<p class="First">Three placebo-controlled studies (two coronary artery bypass graft (CABG) surgery studies largely in patients with medial sternotomy placed on cardiopulmonary bypass and a single general surgery study) were conducted to evaluate the safety of the investigational agent, parecoxib sodium (the parenteral pro-drug of valdecoxib) and valdecoxib.  Patients received parecoxib sodium for at least 3 days and then were transitioned to valdecoxib for a total treatment duration of 10–14 days.  All patients received standard of care <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> during treatment and all patients received low-dose aspirin prior to randomization and throughout the two CABG surgery studies.</p>
<p>In addition to routine adverse event reporting, pre-specified adverse events of interest were adjudicated according to pre-specified definitions by an independent committee who were blinded to treatment assignment.  In the three studies, the overall routine adverse event profiles were similar between active treatments and placebo.</p>
<p>The first CABG surgery study evaluated patients treated with IV parecoxib sodium 40 mg bid for a minimum of 3 days, followed by treatment with valdecoxib 40 mg bid (parecoxib sodium/valdecoxib group) (n=311) or placebo/placebo (n=151) in a 14-day, double-blind placebo-controlled study.  Nine pre-specified adverse event categories were evaluated (cardiovascular <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, new onset or exacerbation of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>/dysfunction, upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> complications, major non-<span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleeds</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, non-infectious pulmonary complications, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>). There was a significantly (p&lt;0.05) greater incidence of cardiovascular/<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>) detected in the parecoxib/valdecoxib treatment group compared to the placebo/placebo treatment group for the IV dosing period (2.2% and 0.0% respectively) and over the entire study period (4.8% and 1.3% respectively).  Surgical <span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">wound complications</span> (most involving the sternal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>) were observed at an increased rate with parecoxib/valdecoxib treatment.</p>
<p>In the second larger CABG surgery study, four pre-specified event categories were evaluated (cardiovascular/thromboembolic; renal dysfunction/<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>; upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>/<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; surgical <span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">wound complication</span>).  Patients were randomized within 24-hours post-CABG surgery to: parecoxib initial dose of 40 mg IV, then 20 mg IV Q12H for a minimum of 3 days followed by valdecoxib PO (20 mg Q12H) (n=544) for the remainder of a 10 day treatment period; placebo IV followed by valdecoxib PO (n=544); or placebo IV followed by placebo PO (n=548).  A significantly (p=0.033) greater incidence of events in the cardiovascular/thromboembolic category was detected in the parecoxib /valdecoxib treatment group (2.0%) compared to the placebo/placebo treatment group (0.5%).  Placebo/valdecoxib treatment was also associated with a higher incidence of CV <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> versus placebo treatment, but this difference did not reach statistical significance.  Three of the cardiovascular <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> in the placebo/valdecoxib treatment group occurred during the placebo treatment period; these patients did not receive valdecoxib.  Pre-specified events that occurred with the highest incidence in all three treatment groups involved the category of surgical <span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">wound complications</span>, including deep surgical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and sternal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing events (see table below).</p>
<table width="75%">
<caption><span>Incidence of Prespecified Adverse Events in CABG Surgery Study 2 [n, (% of patients)]</span></caption>
<col align="left" width="55%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<thead><tr class="First Last">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="center">Placebo/Placebo</th>
<th class="Botrule Lrule" align="center">Placebo/Valdecoxib</th>
<th class="Botrule Lrule Rrule" align="center">Parecoxib/Valdecoxib</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>p&lt;0.05 vs placebo treatment</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">Total Number of Patients Treated<br>  
     (Entire Study and IV Dosing Period)</td>
<td class="Botrule Lrule" align="center">548</td>
<td class="Botrule Lrule" align="center">544</td>
<td class="Botrule Lrule Rrule" align="center">544</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  (Oral Dosing Period)</td>
<td class="Botrule Lrule" align="center">503</td>
<td class="Botrule Lrule" align="center">500</td>
<td class="Botrule Lrule Rrule" align="center">511</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Any Prespecified Adverse Event (Entire Study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">22 (4.0)</span></td>
<td class="Botrule Lrule" align="center">
<span class="Bold">40 (7.4)</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">40 (7.4)</span><a href="#footnote-3" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV dosing period</td>
<td class="Botrule Lrule" align="center">5 (0.9)</td>
<td class="Botrule Lrule" align="center">10 (1.8)</td>
<td class="Botrule Lrule Rrule" align="center">13 (2.4)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">17 (3.4)</td>
<td class="Botrule Lrule" align="center">31 (6.2)<a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Botrule Lrule Rrule" align="center">27 (5.3)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Cardiovascular <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span> (Entire <br>Study) </span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">3 (0.5)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">6 (1.1)</span></td>
<td class="Botrule Lrule Rrule" align="center">
<span class="Bold">11 (2.0)</span><a href="#footnote-3" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV dosing period</td>
<td class="Botrule Lrule" align="center">1 (0.2)</td>
<td class="Botrule Lrule" align="center">3 (0.6)</td>
<td class="Botrule Lrule Rrule" align="center">4 (0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">2 (0.4)</td>
<td class="Botrule Lrule" align="center">3 (0.6)</td>
<td class="Botrule Lrule Rrule" align="center">7 (1.4)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span>/dysfunction Events (Entire Study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">3 (0.5)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">4 (0.7)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">7 (1.3)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV dosing period</td>
<td class="Botrule Lrule" align="center">3 (0.5)</td>
<td class="Botrule Lrule" align="center">4 (0.7)</td>
<td class="Botrule Lrule Rrule" align="center">6 (1.1)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">0 (0.0)</td>
<td class="Botrule Lrule" align="center">0 (0.0)</td>
<td class="Botrule Lrule Rrule" align="center">1 (0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Events (Entire Study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">2 (0.4)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">4 (0.7)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">6 (1.1)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV dosing period</td>
<td class="Botrule Lrule" align="center">1 (0.2)</td>
<td class="Botrule Lrule" align="center">1 (0.2)</td>
<td class="Botrule Lrule Rrule" align="center">2 (0.4)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">1 (0.2)</td>
<td class="Botrule Lrule" align="center">3 (0.6)</td>
<td class="Botrule Lrule Rrule" align="center">4 (0.8)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold"> Surgical <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Events (Entire Study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">16 (2.9)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">27 (5.0)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">20 (3.7)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV dosing period</td>
<td class="Botrule Lrule" align="center">2 (0.4)</td>
<td class="Botrule Lrule" align="center">2 (0.4)</td>
<td class="Botrule Lrule Rrule" align="center">2 (0.4)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">14 (2.8)</td>
<td class="Botrule Lrule" align="center">25 (5.0)</td>
<td class="Botrule Lrule Rrule" align="center">18 (3.5)</td>
</tr>
</tbody>
</table>
<p>General Surgery: In the third study, a large (N=1050) major orthopedic/general surgery trial, patients received an initial dose of parecoxib 40 mg IV, then 20 mg IV Q12H for a minimum of 3 days followed by valdecoxib PO (20 mg Q12H) (n=525) for the remainder of a 10 day treatment period, or placebo IV followed by placebo PO (n=525).  There were no significant differences in the overall safety profile, including the four pre-specified event categories described above for the second CABG surgery study, for parecoxib sodium/valdecoxib compared to placebo treatment in these post-surgical patients (see table below).</p>
<table width="60%">
<caption><span>Incidence of Prespecified Adverse Events in CABG Surgery Study 2 [n, (% of patients)]</span></caption>
<col align="left" width="70%">
<col align="center" width="15%">
<col align="center" width="15%">
<thead><tr class="First Last">
<th class="Botrule Lrule" align="left"></th>
<th class="Botrule Lrule" align="center">Placebo/Placebo</th>
<th class="Botrule Lrule Rrule" align="center">Parecoxib /Valdecoxib</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">Total Number of Patients Treated</td>
<td class="Botrule Lrule" align="center">525</td>
<td class="Botrule Lrule Rrule" align="center">525</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Any Prespecified Adverse Event (Entire Study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">17 (3.2)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">14 (2.7)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV/IM dosing period</td>
<td class="Botrule Lrule" align="center">6 (1.1)</td>
<td class="Botrule Lrule Rrule" align="center">3 (0.6)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">11 (2.1)</td>
<td class="Botrule Lrule Rrule" align="center">11 (2.1)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Cardiovascular <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span> (Entire study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">5 (1.0)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">5 (1.0)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV/IM dosing period</td>
<td class="Botrule Lrule" align="center">1 (0.2)</td>
<td class="Botrule Lrule Rrule" align="center">2 (0.4)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">4 (0.8)</td>
<td class="Botrule Lrule Rrule" align="center">3 (0.6)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span>/dysfunction Events (Entire study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">0 (0.0)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">1 (0.2)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV/IM dosing period</td>
<td class="Botrule Lrule" align="center">0 (0.0)</td>
<td class="Botrule Lrule Rrule" align="center">1 (0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">0 (0.0)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Events (Entire study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">1 (0.2)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">1 (0.2)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV/IM dosing period</td>
<td class="Botrule Lrule" align="center">1 (0.2)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">0 (0.0)</td>
<td class="Botrule Lrule Rrule" align="center">1 (0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="Bold">Surgical <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Events (Entire study)</span></td>
<td class="Botrule Lrule" align="center"><span class="Bold">11 (2.1)</span></td>
<td class="Botrule Lrule Rrule" align="center"><span class="Bold">9 (1.7)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  IV/IM dosing period</td>
<td class="Botrule Lrule" align="center">4 (0.8)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0.0)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">  Oral dosing period</td>
<td class="Botrule Lrule" align="center">7 (1.3)</td>
<td class="Botrule Lrule Rrule" align="center">9 (1.7)</td>
</tr>
</tbody>
</table>
<p>No significant differences were observed between the treatment groups</p>
<p>
											BEXTRA is contraindicated for the treatment of post-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> immediately following coronary artery bypass graft surgery and should not be used in this setting  (See <a href="#Contraindications">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.2"></a><p></p>
<h3>Cardiovascular Safety Analysis from <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span> Studies</h3>
<p class="First">Randomized controlled clinical trials with BEXTRA longer than one year have not been conducted, nor have studies powered to detect differences in cardiovascular events in a chronic setting been conducted.</p>
<p>In an analysis of 10 randomized controlled clinical studies in <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, 4531 patients received BEXTRA in doses ranging from 10 mg to 80 mg for periods of 6 to 52 weeks.  The majority of these patients received BEXTRA for 12 weeks or less.  This analysis compared the incidence of serious cardiovascular events in BEXTRA-treated patients with the incidence of these events in patients receiving placebo (N=1142) or NSAID therapy (N=2261).  In this analysis, no apparent differences were detected in the exposure-adjusted serious cardiovascular <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> rates between patients receiving BEXTRA, placebo and NSAIDs.</p>
<p>BEXTRA has not been studied in clinical trials beyond 12 months duration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.3"></a><p></p>
<h3>Gastrointestinal (GI) Endoscopy Studies with Therapeutic Doses</h3>
<p class="First">Scheduled upper GI endoscopic evaluations were performed with BEXTRA at doses of 10 and 20 mg daily in over 800 OA patients who were enrolled into two randomized 3-month studies using active comparators and placebo controls (Study 3 and Study 4). These studies enrolled patients free of endoscopic <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> at baseline and compared rates of endoscopic <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, defined as any <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">gastroduodenal ulcer</span> seen endoscopically provided it was of "unequivocal depth" and at least 3 mm in diameter.</p>
<p>In both studies, BEXTRA 10 mg daily was associated with a statistically significant lower incidence of endoscopic <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">gastroduodenal ulcers</span> over the study period compared to the active comparators. Figure 1 summarizes the incidence of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">gastroduodenal ulcers</span> in Studies 3 and 4 for the placebo, valdecoxib, and active control arms.</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=CAF64301-262C-45CA-ACD1-A9D6696C584E&amp;name=bextra-image02.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Supratherapeutic_Doses"></a><a name="section-4.4.4"></a><p></p>
<h3>Safety Study with Supratherapeutic Doses</h3>
<p class="First">Scheduled upper GI endoscopic evaluations were performed in a randomized 6-month study of 1217 patients with OA and RA comparing valdecoxib 20 mg BID (40 mg daily) and 40 mg BID (80 mg daily) (4 to 8 times the recommended therapeutic dose) to naproxen 500 mg BID (Study 5).  This study also formally assessed renal events as a primary outcome with supratherapeutic doses of BEXTRA. The renal endpoint was defined as any of the following: new/increase in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, new/increase in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, increase in blood pressure (BP; &gt;20 mm Hg systolic, &gt;10 mm Hg diastolic), new/increase in BP treatment, new/increase in diuretic therapy, creatinine increase over 30% (or &gt;1.2 mg/dL if baseline &lt;0.9 mg/dL), BUN increase over 200% or &gt;50 mg/dL, 24-hr urinary protein increase to &gt;500 mg (if baseline 0–150 mg or &gt;750 if baseline 151–300 or &gt;1000 if baseline 301–500), serum potassium increase to &gt;6 mEq/L, or serum sodium decrease to &lt;130 mEq/L.</p>
<p>Figure 2 summarizes the incidence rates of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">gastroduodenal ulcers</span> and renal events that were seen in Study 5.  BEXTRA 40 mg daily and 80 mg daily were associated with a statistically significant lower incidence of endoscopic <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">gastroduodenal ulcers</span> over the study period compared to naproxen.  The incidence of renal events was significantly different between the BEXTRA 80 mg daily group and naproxen. The clinical relevance of renal events observed with supratherapeutic doses (4 to 8 times the recommended therapeutic dose) of BEXTRA is not known (see <a href="#Renal_Effects">PRECAUTIONS — Renal Effects</a>).</p>
<p class="Bold"><span class="ParagraphCaption">Figure 2 Incidence of Endoscopic <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Gastroduodenal Ulcers</span> and Renal Events in the High-dose Safety Study</span></p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=CAF64301-262C-45CA-ACD1-A9D6696C584E&amp;name=bextra-image03.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.5"></a><p></p>
<h3>Renal Safety at the Therapeutic Chronic Dose</h3>
<p class="First">The renal effects of valdecoxib compared with placebo and conventional NSAIDs were also assessed by prospectively designed pooled analyses of renal events data (see definition above —<a href="#Supratherapeutic_Doses">Supratherapeutic Doses</a>) from five placebo- and active-controlled 12-week <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> trials that included 995 OA or RA patients given valdecoxib 10 mg daily.  The incidence of renal events observed in this analysis with valdecoxib 10 mg daily (3%), ibuprofen 800 mg TID (7%), naproxen 500 mg BID (2%) and diclofenac 75 mg BID (4%) were significantly higher than placebo-treated patients (1%).  In all treatment groups, the majority of renal events were either due to the occurrence of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or worsening BP.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4247120" conceptname="Gastrointestinal ulcer">Gastrointestinal Ulcers</span> in High-Risk Patients</h3>
<p class="First">Subset analyses were performed of patients with risk factors (age, concomitant low-dose aspirin use, history of prior <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease) enrolled in four upper GI endoscopic studies. Table 3 summarizes the trends seen.</p>
<table width="100%">
<caption><span>Table 3 Incidence of Endoscopic <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Gastroduodenal Ulcers</span> in Patients With and Without Selected Risk Factors</span></caption>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First">
<th class="Lrule" align="left"></th>
<th class="Botrule Lrule" align="center" colspan="2">Placebo-controlled Studies</th>
<th class="Botrule Lrule Rrule" align="center" colspan="4">Active-controlled Studies</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left">Risk Factor</th>
<th class="Lrule" align="center">Placebo</th>
<th class="Lrule" align="center">Valdecoxib<br>(10–20 mg daily)</th>
<th class="Lrule" align="center">Valdecoxib<br>(10–80 mg daily)</th>
<th class="Lrule" align="center">Ibuprofen<br>800 mg TID</th>
<th class="Lrule" align="center">Naproxen<br>500 mg BID</th>
<th class="Lrule Rrule" align="center">Diclofenac<br>75 mg BID</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="7">No statistical conclusions can be drawn from these comparisons.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Age</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  &lt;65 yrs</td>
<td class="Lrule" align="center">3.7% (8/219) </td>
<td class="Lrule" align="center">3.5% (17/484) </td>
<td class="Lrule" align="center">3.7% (48/1306) </td>
<td class="Lrule" align="center">8.2% (9/110) </td>
<td class="Lrule" align="center">12.8% (51/397) </td>
<td class="Lrule Rrule" align="center">13.2% (34/258) </td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  ≥65 yrs</td>
<td class="Botrule Lrule" align="center">5.8% (8/137)</td>
<td class="Botrule Lrule" align="center">4.6% (12/262)</td>
<td class="Botrule Lrule" align="center">7.6% (43/568)</td>
<td class="Botrule Lrule" align="center">21.6% (16/74)</td>
<td class="Botrule Lrule" align="center">22.0% (33/150)</td>
<td class="Botrule Lrule Rrule" align="center">18.2% (25/137)</td>
</tr>
<tr>
<td class="Lrule" align="left">Concomitant Low Dose Aspirin Use</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  no</td>
<td class="Lrule" align="center">4.4% (13/298) </td>
<td class="Lrule" align="center">3.2% (21/650) </td>
<td class="Lrule" align="center">3.8% (64/1671) </td>
<td class="Lrule" align="center">9.8% (15/153) </td>
<td class="Lrule" align="center">16.0% (75/468) </td>
<td class="Lrule Rrule" align="center">12.8% (45/351) </td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">  yes</td>
<td class="Botrule Lrule" align="center">5.2% (3/58)</td>
<td class="Botrule Lrule" align="center">8.3% (8/96)</td>
<td class="Botrule Lrule" align="center">13.3%(27/203)</td>
<td class="Botrule Lrule" align="center">32.3% (10/31)</td>
<td class="Botrule Lrule" align="center">11.4% (9/79)</td>
<td class="Botrule Lrule Rrule" align="center">31.8% (14/44)</td>
</tr>
<tr>
<td class="Lrule" align="left">History of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span> Disease</td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  no</td>
<td class="Lrule" align="center">4.4% (14/317) </td>
<td class="Lrule" align="center">3.4% (22/647) </td>
<td class="Lrule" align="center">4.1% (68/1666) </td>
<td class="Lrule" align="center">13.8% (22/160) </td>
<td class="Lrule" align="center">13.3% (63/475) </td>
<td class="Lrule Rrule" align="center">14.7% (52/354) </td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  yes</td>
<td class="Lrule" align="center">5.1% (2/39)</td>
<td class="Lrule" align="center">7.1% (7/99)</td>
<td class="Lrule" align="center">11.1% (23/208)</td>
<td class="Lrule" align="center">12.5% (3/24)</td>
<td class="Lrule" align="center">29.2% (21/72)</td>
<td class="Lrule Rrule" align="center">17.1% (7/41)</td>
</tr>
</tbody>
</table>
<p>The correlation between findings of endoscopic studies, and the incidence of clinically significant serious upper GI events has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Platelets"></a><a name="section-4.4.7"></a><p></p>
<h3>Platelets</h3>
<p class="First">In four clinical studies with young and elderly (≥65 years) subjects, single and multiple doses up to 7 days of BEXTRA 10 to 40 mg BID had no effect on platelet aggregation.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">BEXTRA Tablets are indicated:</p>
<ul>
<li>For relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span> and adult <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</li>
<li>For the treatment of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">primary dysmenorrhea</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contraindications"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">BEXTRA should not be given to patients who have demonstrated allergic-type reactions to sulfonamides.</p>
<p>BEXTRA Tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to valdecoxib. BEXTRA should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or NSAIDs.  Severe, rarely fatal, anaphylactic-like reactions to NSAIDs are possible in such patients (see <a href="#Anaphylactoid_Reactions">WARNINGS — <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a>, and <a href="#Preexisting_Asthma">PRECAUTIONS — Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>)</a>.</p>
<p>BEXTRA is contraindicated for the treatment of post-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> immediately following coronary artery bypass graft (CABG) surgery and should not be used in this setting.  (See<a href="#Safety_Studies"> CLINICAL STUDIES — Safety Studies</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Gastrointestinal"></a><a name="section-7.1"></a><p></p>
<h2>Gastrointestinal (GI) Effects — Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation </h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span> such as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration and perforation of the stomach, small intestine or large intestine can occur at any time with or without warning symptoms in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). Minor gastrointestinal problems such as <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> are common and may also occur at any time during NSAID therapy. Therefore, physicians and patients should remain alert for ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> even in the absence of previous GI tract symptoms. Patients should be informed about the signs and symptoms of serious GI toxicity and the steps to take if they occur. The utility of periodic laboratory monitoring has not been demonstrated, nor has it been adequately assessed. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. It has been demonstrated that upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or perforation caused by NSAIDs appear to occur in approximately 1% of patients treated for 3 to 6 months and 2–4% of patients treated for one year. These trends continue, thus increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.</p>
<p>NSAIDs should be prescribed with extreme caution in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population.  For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</p>
<p>Studies have shown that patients with a <span class="Italics">prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span></span> and who use NSAIDs, have a greater than 10-fold higher risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> than patients with neither of these risk factors.  In addition to a past history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease, pharmacoepidemiological studies have identified several other co-therapies or co-morbid conditions that may increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> such as: treatment with oral corticosteroids, treatment with anticoagulants, longer duration of NSAID therapy, smoking, <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, older age, and poor general health status. (See <a href="#Safety_Studies">CLINICAL STUDIES — Safety Studies</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Serious_Skin_Reactions"></a><a name="section-7.2"></a><p></p>
<h2>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First"><span class="Bold">Valdecoxib contains a sulfonamide moiety and patients with a known history of a <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">sulfonamide allergy</span> may be at a greater risk of <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Patients without a history of <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">sulfonamide allergy</span> may also be at risk for serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span></p>
<p><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, have been reported through postmarketing surveillance in patients receiving BEXTRA (see <a href="#Postmarketing_Experience">ADVERSE REACTIONS — Postmarketing Experience</a>). Fatalities due to <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported. Patients appear to be at higher risk for these events early in the course of therapy, with the onset of the event occurring in the majority of cases within the first two weeks of treatment. BEXTRA should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, mucosal lesions or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been reported with other COX-2 inhibitors during postmarketing experience.  The reported rate of these events appears to be greater for BEXTRA as compared to other COX-2 agents (see <a href="#Boxed">Boxed Warning — Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>)</a>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Anaphylactoid_Reactions"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">In postmarketing experience, cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) have been reported in patients receiving BEXTRA (see <a href="#Postmarketing_Experience">ADVERSE REACTIONS — Postmarketing Experience</a>).  These cases have occurred in patients with and without a history of allergic-type reactions to sulfonamides (see <a href="#Contraindications">CONTRAINDICATIONS</a>).  BEXTRA should not be given to patients with the aspirin triad.  This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs (see <a href="#Contraindications">CONTRAINDICATIONS</a> and <a href="#Preexisting_Asthma">PRECAUTIONS — Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a>).</p>
<p>Emergency help should be sought in cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Coronary Artery Bypass Graft Surgery</h2>
<p class="First"><span class="Bold">Patients treated with BEXTRA for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following coronary artery bypass graft surgery have a higher risk for cardiovascular/<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, deep surgical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or sternal <span class="product-label-link" type="condition" conceptid="4177613" conceptname="Wound pain">wound complications</span>.  BEXTRA is therefore contraindicated for the treatment of <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span> following CABG surgery. (See<a href="#Contraindications"> CONTRAINDICATIONS</a> and <a href="#Safety_Studies">CLINICAL STUDIES-Safety Studies</a>)</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Advanced_Renal_Disease"></a><a name="section-7.5"></a><p></p>
<h2>Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h2>
<p class="First">No information is available regarding the safe use of BEXTRA Tablets in patients with advanced kidney disease. Therefore, treatment with BEXTRA is not recommended in these patients. If therapy with BEXTRA must be initiated, close monitoring of the patient's kidney function is advisable (see <a href="#Renal_Effects">PRECAUTIONS — Renal Effects</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">In late pregnancy, BEXTRA should be avoided because it may cause premature closure of the ductus arteriosus.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="34072-9">
<a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">BEXTRA Tablets cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness.  Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</p>
<p>The pharmacological activity of valdecoxib in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Hepatic Effects</h2>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs.  These laboratory abnormalities may progress, may remain unchanged, or may remain transient with continuing therapy.  Rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (some with fatal outcome) have been reported with NSAIDs.  In controlled clinical trials of valdecoxib, the incidence of borderline (defined as 1.2- to 3.0-fold) elevations of liver tests was 8.0% for valdecoxib and 8.4% for placebo, while approximately 0.3% of patients taking valdecoxib, and 0.2% of patients taking placebo, had notable (defined as greater than 3-fold) elevations of ALT or AST.</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with BEXTRA.  If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>), BEXTRA should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Renal_Effects"></a><a name="section-8.3"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion.  In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and Angiotensin Converting Enzyme (ACE) inhibitors, and the elderly.  Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. </p>
<p>Caution should be used when initiating treatment with BEXTRA in patients with considerable <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>.  It is advisable to rehydrate patients first and then start therapy with BEXTRA.  Caution is also recommended in patients with preexisting kidney disease. (See <a href="#Advanced_Renal_Disease">WARNINGS — Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<h2>Hematological Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving BEXTRA.  Patients on long-term treatment with BEXTRA should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>BEXTRA does not generally affect platelet counts, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT), or <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (APTT), and does not appear to inhibit platelet aggregation at indicated dosages (see<a href="#Platelets"> CLINICAL STUDIES — Safety Studies — Platelets</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking BEXTRA (see <a href="#Adverse_Reactions">ADVERSE REACTIONS</a>). Therefore, BEXTRA should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Preexisting_Asthma"></a><a name="section-8.6"></a><p></p>
<h2>Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.  The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, which can be fatal.  Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, BEXTRA should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.7"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">BEXTRA can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, more serious GI side effects, which may result in hospitalization and even fatal outcomes.  Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative sign or symptoms.  Patients should be apprised of the importance of this follow-up (see<a href="#Gastrointestinal"> WARNINGS — Gastrointestinal (GI) Effects — Risk of GI Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a>).</p>
<p>Patients should report to their physicians, signs or symptoms of gastrointestinal ulceration or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>Patients should be instructed to discontinue treatment and seek medical attention at the first signs of a <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> (<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, or mucosal lesions) (see <a href="#Serious_Skin_Reactions">WARNINGS — Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a>).</p>
<p>Patients should also be instructed to seek immediate emergency help in the case of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (see <a href="#Anaphylactoid_Reactions">WARNINGS — <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a>).</p>
<p>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and flu-like symptoms).  If these occur, patients should be instructed to stop therapy and seek immediate medical attention.</p>
<p>In late pregnancy, BEXTRA should be avoided because it may cause premature closure of the ductus arteriosus.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8.8"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs and symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Drug_Interactions"></a><a name="section-8.9"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The drug interaction studies with valdecoxib were performed both with valdecoxib and a rapidly hydrolyzed intravenous prodrug form. The results from trials using the intravenous prodrug are reported in this section as they relate to the role of valdecoxib in drug interactions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.1"></a><p></p>
<h3>General</h3>
<p class="First">In humans, valdecoxib metabolism is predominantly mediated via CYP 3A4 and 2C9 with glucuronidation being a further (20%) route of metabolism.  In vitro studies indicate that valdecoxib is a moderate inhibitor of CYP 2C19 (IC50 = 6 µg/mL or 19 µM) and 2C9 (IC50 = 13 µg/mL or 41 µM), and a weak inhibitor of CYP 2D6 (IC50 = 31 µg/mL or 100 µM) and 3A4 (IC50 = 44 µg/mL or 141 µM). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.2"></a><p></p>
<h3>Aspirin</h3>
<p class="First">Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone. Because of its lack of anti-platelet effect valdecoxib is not a substitute for aspirin for cardiovascular prophylaxis.</p>
<p>In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.3"></a><p></p>
<h3>Methotrexate</h3>
<p class="First">Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.4"></a><p></p>
<h3>ACE-inhibitors</h3>
<p class="First">Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.5"></a><p></p>
<h3>Furosemide</h3>
<p class="First">Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.  This response has been attributed to inhibition of renal prostaglandin synthesis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.6"></a><p></p>
<h3>Anticonvulsants (Phenytoin)</h3>
<p class="First">Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when coadministered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer). Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration. Valdecoxib did not have a statistically significant effect on the pharmacokinetics of phenytoin (a CYP 2C9 and CYP 2C19 substrate).</p>
<p>Drug interaction studies with other anticonvulsants have not been conducted.  Routine monitoring should be performed when therapy with BEXTRA is either initiated or discontinued in patients on anticonvulsant therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.7"></a><p></p>
<h3>Dextromethorphan</h3>
<p class="First">Dextromethorphan is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.  Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.  Even so, dextromethorphan plasma concentrations in the presence of high doses of valdecoxib were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.8"></a><p></p>
<h3>Lithium</h3>
<p class="First">Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.  Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium. Lithium carbonate (450 mg BID for 7 days) had no effect on valdecoxib pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.9"></a><p></p>
<h3>Warfarin</h3>
<p class="First">The effect of valdecoxib on the anticoagulant effect of warfarin (1–8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days. Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (<span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, measured as INR) of warfarin. While mean INR values were only slightly increased with coadministration of valdecoxib, the day-to-day variability in individual INR values was increased.  Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.10"></a><p></p>
<h3>Fluconazole and Ketoconazole</h3>
<p class="First">Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.  Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of valdecoxib.  Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.11"></a><p></p>
<h3>Glyburide</h3>
<p class="First">Glyburide is a CYP 2C9 substrate.  Coadministration of valdecoxib (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide. Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2–7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.  Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2–7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC<span class="Sub">(0–12hr</span>) and a 16% increase in glyburide C<span class="Sub">max </span>leading to a 16%decrease in glucose AUC<span class="Sub">(0–24hr</span>).  Insulin parameters were not affected.  Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated. Coadministration of glyburide with doses higher than 40 mg valdecoxib (e.g., 40 mg BID) has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.12"></a><p></p>
<h3>Omeprazole</h3>
<p class="First">Omeprazole is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor. Valdecoxib steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of omeprazole (40 mg QD). Coadministration with valdecoxib increased exposure of omeprazole (AUC) by 46%.  Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of omeprazole and valdecoxib.  However, because higher doses (up to 360 mg QD) of omeprazole are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for omeprazole is recommended at current doses.  Coadministration of valdecoxib with doses higher than 40 mg QD omeprazole has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.13"></a><p></p>
<h3>Oral Contraceptives</h3>
<p class="First">  Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg/0.035 mg combination, Ortho-Novum 1/35<span class="Sup">®</span>).  Coadministration of valdecoxib and Ortho-Novum 1/35<span class="Sup">®</span> increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively. Although there is little risk for loss of contraceptive efficacy, the clinical significance of these increased exposures in terms of safety is not known.  These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.14"></a><p></p>
<h3>Diazepam</h3>
<p class="First">Diazepam (Valium<span class="Sup">®</span>) is a CYP 3A4 and CYP 2C19 substrate.  Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days. Although the magnitude of changes in diazepam plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.  Patients should be cautioned against engaging in hazardous activities requiring complete mental alertness such as operating machinery or driving a motor vehicle.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.10"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Valdecoxib was not carcinogenic in rats given oral doses up to 7.5 mg/kg/day for males and 1.5 mg/kg/day for females (equivalent to approximately 2- to 6-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>) or in mice given oral doses up to 25 mg/kg/day for males and 50 mg/kg/day for females (equivalent to approximately 0.6- to 2.4-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>) for two years. </p>
<p>Valdecoxib was not mutagenic in an Ames test or a mutation assay in Chinese hamster ovary (CHO) cells, nor was it clastogenic in a chromosome aberration assay in CHO cells or in an <span class="Italics">in vivo</span> micronucleus test in rat bone marrow.</p>
<p>Valdecoxib did not impair male rat fertility at oral doses up to 9.0 mg/kg/day (equivalent to approximately 3- to 6-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>).  In female rats, a decrease in ovulation with increased pre- and post-implantation loss resulted in decreased live embryos/fetuses at doses ≥2 mg/kg/day (equivalent to approximately 2-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span> for valdecoxib). The effects on female fertility were reversible. This effect is expected with inhibition of prostaglandin synthesis and is not the result of irreversible alteration of female reproductive function.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.11"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"></p>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.11.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.11.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">The incidence of fetuses with skeletal anomalies such as semi-bipartite thoracic vertebra centra and fused sternebrae was slightly higher in rabbits at an oral dose of 40 mg/kg/day (equivalent to approximately 72-fold human exposures at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>) throughout organogenesis. Valdecoxib was not teratogenic in rabbits up to an oral dose of 10 mg/kg/day (equivalent to approximately 8-fold human exposures at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>).</p>
<p>Valdecoxib was not teratogenic in rats up to an oral dose of 10 mg/kg/day (equivalent to approximately 19-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>).  There are no studies in pregnant women.  However, valdecoxib crosses the placenta in rats and rabbits.  BEXTRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.11.2"></a><p></p>
<h3>Non-teratogenic Effects</h3>
<p class="First">Valdecoxib caused increased pre- and post-implantation loss with reduced live fetuses at oral doses ≥10 mg/kg/day (equivalent to approximately 19-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>) in rats and an oral dose of 40 mg/kg/day (equivalent to approximately 72-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>) in rabbits throughout organogenesis.  In addition, reduced neonatal survival and decreased neonatal body weight when rats were treated with valdecoxib at oral doses ≥6 mg/kg/day (equivalent to approximately 7-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>) throughout organogenesis and lactation period. No studies have been conducted to evaluate the effect of valdecoxib on the closure of the ductus arteriosus in humans.  Therefore, as with other drugs known to inhibit prostaglandin synthesis, use of BEXTRA during the third trimester of pregnancy should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.12"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Valdecoxib produced no evidence of delayed labor or parturition at oral doses up to 10 mg/kg/day in rats (equivalent to approximately 19-fold human exposure at 20 mg QD as measured by the AUC<span class="Sub">(0–24hr)</span>).  The effects of BEXTRA on labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.13"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Valdecoxib and its active metabolite are excreted in the milk of lactating rats.  It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk, and because of the potential for adverse reactions in nursing infants from BEXTRA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother and the importance of nursing to the infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.14"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of BEXTRA in pediatric patients below the age of 18 years have not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.15"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of the patients who received BEXTRA in <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> clinical trials of three months duration, or greater, approximately 2100 were 65 years of age or older, including 570 patients who were 75 years or older.  No overall differences in effectiveness were observed between these patients and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse_Reactions"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Of the patients treated with BEXTRA Tablets in controlled <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> trials, 2665 were patients with OA, and 2684 were patients with RA.  More than 4000 patients have received a chronic total daily dose of BEXTRA 10 mg or more. More than 2800 patients have received BEXTRA 10 mg/day, or more, for at least 6 months and 988 of these have received BEXTRA for at least 1 year.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First">Table 4 lists all adverse events, regardless of causality, that occurred in ≥2.0% of patients receiving BEXTRA 10 and 20 mg/day in studies of three months or longer from 7 controlled studies conducted in patients with OA or RA that included a placebo and/or a positive control group. </p>
<table width="75%">
<caption><span>Table 4 Adverse Events with Incidence ≥2.0% in Valdecoxib Treatment Groups: Controlled <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> Trials of Three Months or Longer</span></caption>
<col align="left">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<col align="center">
<thead>
<tr class="First">
<th class="Lrule" align="left" colspan="2"></th>
<th class="Botrule Lrule Rrule" align="center" colspan="5">(Total Daily Dose)</th>
</tr>
<tr>
<th class="Botrule Lrule" align="left" colspan="2"></th>
<th class="Botrule Lrule" align="center" colspan="2">Valdecoxib </th>
<th class="Lrule" align="center">Diclofenac</th>
<th class="Lrule" align="center">Ibuprofen</th>
<th class="Lrule Rrule" align="center">Naproxen</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left">Adverse Event<br>Number Treated</th>
<th class="Lrule" align="center">Placebo <br>973</th>
<th class="Lrule" align="center">10 mg<br>1214</th>
<th class="Lrule" align="center">20 mg<br>1358</th>
<th class="Lrule" align="center">150 mg<br>711</th>
<th class="Lrule" align="center">2400 mg<br>207</th>
<th class="Lrule Rrule" align="center">1000 mg<br>766</th>
</tr>
</thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="7"><span class="Bold">Autonomic <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Lrule" align="center">0.6</td>
<td class="Botrule Lrule" align="center">1.6</td>
<td class="Botrule Lrule" align="center">2.1</td>
<td class="Botrule Lrule" align="center">2.5</td>
<td class="Botrule Lrule" align="center">2.4</td>
<td class="Botrule Lrule Rrule" align="center">1.7</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Botrule Lrule" align="center">1.6</td>
<td class="Botrule Lrule" align="center">1.6</td>
<td class="Botrule Lrule" align="center">2.7</td>
<td class="Botrule Lrule" align="center">2.8</td>
<td class="Botrule Lrule" align="center">1.4</td>
<td class="Botrule Lrule Rrule" align="center">1.0</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></td>
<td class="Botrule Lrule" align="center">0.7</td>
<td class="Botrule Lrule" align="center">2.4</td>
<td class="Botrule Lrule" align="center">3.0</td>
<td class="Botrule Lrule" align="center">3.2</td>
<td class="Botrule Lrule" align="center">2.9</td>
<td class="Botrule Lrule Rrule" align="center">2.1</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td class="Botrule Lrule" align="center">2.2</td>
<td class="Botrule Lrule" align="center">2.0</td>
<td class="Botrule Lrule" align="center">2.2</td>
<td class="Botrule Lrule" align="center">3.1</td>
<td class="Botrule Lrule" align="center">2.9</td>
<td class="Botrule Lrule Rrule" align="center">2.0</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Injury accidental</td>
<td class="Botrule Lrule" align="center">2.8</td>
<td class="Botrule Lrule" align="center">4.0</td>
<td class="Botrule Lrule" align="center">3.7</td>
<td class="Botrule Lrule" align="center">3.9</td>
<td class="Botrule Lrule" align="center">3.9</td>
<td class="Botrule Lrule Rrule" align="center">3.0</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7"><span class="Bold">Central and Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Lrule" align="center">2.1</td>
<td class="Botrule Lrule" align="center">2.6</td>
<td class="Botrule Lrule" align="center">2.7</td>
<td class="Botrule Lrule" align="center">4.2</td>
<td class="Botrule Lrule" align="center">3.4</td>
<td class="Botrule Lrule Rrule" align="center">2.7</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule" align="center">7.1</td>
<td class="Botrule Lrule" align="center">4.8</td>
<td class="Botrule Lrule" align="center">8.5</td>
<td class="Botrule Lrule" align="center">6.6</td>
<td class="Botrule Lrule" align="center">4.3</td>
<td class="Botrule Lrule Rrule" align="center">5.5</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7"><span class="Bold">Gastrointestinal System Disorders</span></td></tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal fullness</span></td>
<td class="Botrule Lrule" align="center">2.0</td>
<td class="Botrule Lrule" align="center">2.1</td>
<td class="Botrule Lrule" align="center">1.9</td>
<td class="Botrule Lrule" align="center">3.0</td>
<td class="Botrule Lrule" align="center">2.9</td>
<td class="Botrule Lrule Rrule" align="center">2.5</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Botrule Lrule" align="center">6.3</td>
<td class="Botrule Lrule" align="center">7.0</td>
<td class="Botrule Lrule" align="center">8.2</td>
<td class="Botrule Lrule" align="center">17.0</td>
<td class="Botrule Lrule" align="center">8.2</td>
<td class="Botrule Lrule Rrule" align="center">10.1</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Lrule" align="center">4.2</td>
<td class="Botrule Lrule" align="center">5.4</td>
<td class="Botrule Lrule" align="center">6.0</td>
<td class="Botrule Lrule" align="center">10.8</td>
<td class="Botrule Lrule" align="center">3.9</td>
<td class="Botrule Lrule Rrule" align="center">4.7</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Lrule" align="center">6.3</td>
<td class="Botrule Lrule" align="center">7.9</td>
<td class="Botrule Lrule" align="center">8.7</td>
<td class="Botrule Lrule" align="center">13.4</td>
<td class="Botrule Lrule" align="center">15.0</td>
<td class="Botrule Lrule Rrule" align="center">12.9</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Botrule Lrule" align="center">4.1</td>
<td class="Botrule Lrule" align="center">2.9</td>
<td class="Botrule Lrule" align="center">3.5</td>
<td class="Botrule Lrule" align="center">3.1</td>
<td class="Botrule Lrule" align="center">7.7</td>
<td class="Botrule Lrule Rrule" align="center">5.4</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule" align="center">5.9</td>
<td class="Botrule Lrule" align="center">7.0</td>
<td class="Botrule Lrule" align="center">6.3</td>
<td class="Botrule Lrule" align="center">8.4</td>
<td class="Botrule Lrule" align="center">7.7</td>
<td class="Botrule Lrule Rrule" align="center">8.7</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7"><span class="Bold">Musculoskeletal System Disorders</span></td></tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule Lrule" align="center">1.6</td>
<td class="Botrule Lrule" align="center">2.0</td>
<td class="Botrule Lrule" align="center">1.9</td>
<td class="Botrule Lrule" align="center">2.4</td>
<td class="Botrule Lrule" align="center">2.4</td>
<td class="Botrule Lrule Rrule" align="center">1.4</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td></tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Botrule Lrule" align="center">2.2</td>
<td class="Botrule Lrule" align="center">2.6</td>
<td class="Botrule Lrule" align="center">1.8</td>
<td class="Botrule Lrule" align="center">1.1</td>
<td class="Botrule Lrule" align="center">3.4</td>
<td class="Botrule Lrule Rrule" align="center">3.4</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Botrule Lrule" align="center">6.0</td>
<td class="Botrule Lrule" align="center">6.7</td>
<td class="Botrule Lrule" align="center">5.7</td>
<td class="Botrule Lrule" align="center">6.3</td>
<td class="Botrule Lrule" align="center">4.3</td>
<td class="Botrule Lrule Rrule" align="center">6.4</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="7"><span class="Bold">Skin and Appendages Disorders</span></td></tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule" align="center">1.0</td>
<td class="Lrule" align="center">1.4</td>
<td class="Lrule" align="center">2.1</td>
<td class="Lrule" align="center">1.5</td>
<td class="Lrule" align="center">0.5</td>
<td class="Lrule Rrule" align="center">1.4</td>
</tr>
</tbody>
</table>
<p>In these placebo- and active-controlled clinical trials, the discontinuation rate due to adverse events was 7.5% for <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> patients receiving valdecoxib 10 mg daily, 7.9% for <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> patients receiving valdecoxib 20 mg daily and 6.0%for patients receiving placebo.</p>
<p>In the seven controlled OA and RA studies, the following adverse events occurred in 0.1–1.9% of patients treated with BEXTRA 10–20 mg daily, regardless of causality.</p>
<p><span class="Bold Italics">Application site disorders:</span> <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">dermatitis contact</span></p>
<p><span class="Bold Italics">Cardiovascular:</span> Aggravated <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4311963" conceptname="Aneurysm">aneurysm</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disorder</span>, <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">heart murmur</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p><span class="Bold Italics">Central, peripheral nervous system:</span> <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">Cerebrovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Bold Italics">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">Goiter</span></p>
<p><span class="Bold Italics">Female reproductive</span>: <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">leukorrhea</span>, <span class="product-label-link" type="condition" conceptid="4163232" conceptname="Mastitis">mastitis</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, menstrual <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span></p>
<p><span class="Bold Italics">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="437671" conceptname="Abnormal feces">Abnormal stools</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4150051" conceptname="Diverticulum">diverticulosis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span> <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">hiatal hernia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, stool frequency increased, tenesmus, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="Bold Italics">General</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy aggravated</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span> NOS, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">edema generalized</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, <span class="product-label-link" type="condition" conceptid="4195873" conceptname="Breath smells unpleasant">halitosis</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">periorbital swelling</span>, peripheral <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="Bold Italics">Hearing and vestibular:</span> Ear abnormality, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Bold Italics">Heart rate and rhythm: </span><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold Italics">Hemic: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p>
<p><span class="Bold Italics">Liver and biliary system:</span> <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Hepatic function abnormal</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, ALT increased, AST increased</p>
<p><span class="Bold Italics">Male reproductive:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>, <span class="product-label-link" type="condition" conceptid="196734" conceptname="Disorder of prostate">prostatic disorder</span></p>
<p><span class="Bold Italics">Metabolic and nutritional:</span> Alkaline phosphatase increased, BUN increased, CPK increased, creatinine increased, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, LDH increased, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> increased, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span></p>
<p><span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> accidental, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">neck stiffness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4168183" conceptname="Synovitis">synovitis</span>, <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span></p>
<p><span class="Bold Italics">Neoplasm:</span> Breast neoplasm, <span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipoma</span>, malignant <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cyst</span></p>
<p><span class="Bold Italics">Platelets (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or clotting):</span> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> NOS, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Bold Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, appetite increased, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression aggravated</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, morbid dreaming, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Bold Italics">Resistance mechanism disorders:</span> Herpes simplex, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">infection fungal</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> soft tissue, <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">infection viral</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4080452" conceptname="Anogenital candidiasis">moniliasis genital</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span></p>
<p><span class="Bold Italics">Respiratory:</span> Abnormal breath sounds, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="78786" conceptname="Pleurisy">pleurisy</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span></p>
<p><span class="Bold Italics">Skin and appendages: </span><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">dermatitis fungal</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular, <span class="product-label-link" type="condition" conceptid="4179347" conceptname="Psoriasiform dermatitis">rash psoriaform</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">skin dry</span>, skin <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulceration</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold Italics">Special senses:</span> <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></p>
<p><span class="Bold Italics">Urinary system:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, micturition frequency increased, <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">pyuria</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p>
<p><span class="Bold Italics">Vascular:</span> <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">Claudication intermittent</span>, <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangioma acquired</span>, <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicose vein</span></p>
<p><span class="Bold Italics">Vision:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span></p>
<p><span class="Bold Italics">White cell and RES disorders:</span> <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="439840" conceptname="Lymphangitis">lymphangitis</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span></p>
<p>Other serious adverse events that were reported rarely (estimated &lt;0.1%) in clinical trials, regardless of causality, in patients taking BEXTRA:</p>
<p><span class="Bold Italics">Autonomic <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">nervous system disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">Hypertensive encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span></p>
<p><span class="Bold Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">Abnormal ECG</span>, <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, carotid stenosis, <span class="product-label-link" type="condition" conceptid="4134723" conceptname="Coronary artery thrombosis">coronary thrombosis</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">heart valve disorders</span>, <span class="product-label-link" type="condition" conceptid="443962" conceptname="Mitral valve regurgitation">mitral insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span></p>
<p><span class="Bold Italics">Central, peripheral nervous system:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></p>
<p><span class="Bold Italics">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">Hyperparathyroidism</span></p>
<p><span class="Bold Italics">Female reproductive:</span> <span class="product-label-link" type="condition" conceptid="192367" conceptname="Dysplasia of cervix">Cervical dysplasia</span></p>
<p><span class="Bold Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">Appendicitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="22955" conceptname="Perforation of esophagus">esophageal perforation</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span></p>
<p><span class="Bold Italics">Hemic:</span> <span class="product-label-link" type="condition" conceptid="4027114" conceptname="Pseudolymphoma">Lymphoma-like disorder</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></p>
<p><span class="Bold Italics">Liver and biliary system:</span> <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span> </p>
<p><span class="Bold Italics">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></p>
<p><span class="Bold Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">Pathological fracture</span>, <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span></p>
<p><span class="Bold Italics">Neoplasm:</span> Benign brain neoplasm, bladder carcinoma, carcinoma, gastric carcinoma, prostate carcinoma, pulmonary carcinoma</p>
<p><span class="Bold Italics">Platelets (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or clotting):</span> <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></p>
<p><span class="Bold Italics">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Manic reaction</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span></p>
<p><span class="Bold Italics">Renal: </span><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span></p>
<p><span class="Bold Italics">Resistance mechanism disorders:</span> <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p>
<p><span class="Bold Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, <span class="product-label-link" type="condition" conceptid="254662" conceptname="Pulmonary infarction">pulmonary infarction</span>, <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span></p>
<p><span class="Bold Italics">Skin:</span> Basal cell carcinoma, malignant melanoma</p>
<p><span class="Bold Italics">Urinary system:</span> <span class="product-label-link" type="condition" conceptid="198199" conceptname="Pyelonephritis">Pyelonephritis</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">renal calculus</span></p>
<p><span class="Bold Italics">Vision:</span> <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">Retinal detachment</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Postmarketing_Experience"></a><a name="section-9.2"></a><p></p>
<h2>Postmarketing Experience</h2>
<p class="First">The following reactions have been identified during postmarketing use of BEXTRA.  These reactions have been chosen for inclusion either due to their seriousness, reporting frequency, possible causal relationship to BEXTRA, or a combination of these factors.  Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Bold Italics">General:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>)</p>
<p><span class="Bold Italics">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></p>
<p><span class="Bold Italics">Skin and appendages:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Symptoms following acute NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> are usually limited to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally reversible with supportive care.  <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur.  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur, but are rare.</p>
<p><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported with therapeutic ingestion of NSAIDs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>Patients should be managed by symptomatic and supportive care following an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  There are no specific antidotes.  Hemodialysis removed only about 2% of administered valdecoxib from the systemic circulation of 8 patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> and, based on its degree of plasma protein binding (&gt;98%), dialysis is unlikely to be useful in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.  Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalinization of urine, or hemoperfusion also may not be useful due to high protein binding.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">Osteoarthritis</span> and Adult <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">Rheumatoid Arthritis</span></h2>
<p class="First">The recommended dose of BEXTRA Tablets for the relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> is 10 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Primary Dysmenorrhea</span></h2>
<p class="First">The recommended dose of BEXTRA Tablets for treatment of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">primary dysmenorrhea</span> is 20 mg twice daily, as needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">BEXTRA Tablets 10 mg are white, film-coated, and capsule-shaped, debossed "10" on one side with a four pointed star shape on the other, supplied as:</p>
<table>
<col align="left">
<col align="left">
<tbody class="Headless">
<tr class="First">
<th align="left">NDC Number	</th>
<th align="left">Size</th>
</tr>
<tr>
<td align="left">0025-1975-31</td>
<td align="left">Bottle of 100</td>
</tr>
<tr>
<td align="left">0025-1975-51</td>
<td align="left">Bottle of 500</td>
</tr>
<tr class="Last">
<td align="left">0025-1975-34</td>
<td align="left">Carton of 100 unit dose</td>
</tr>
</tbody>
</table>
<p>BEXTRA Tablets 20 mg are white, film-coated, and capsule-shaped, debossed "20" on one side with a four pointed star shape on the other, supplied as:</p>
<table>
<col align="left">
<col align="left">
<tbody class="Headless">
<tr class="First">
<th align="left">NDC Number</th>
<th align="left">Size</th>
</tr>
<tr>
<td align="left">0025-1980-31</td>
<td align="left">Bottle of 100</td>
</tr>
<tr>
<td align="left">0025-1980-51</td>
<td align="left">Bottle of 500</td>
</tr>
<tr class="Last">
<td align="left">0025-1980-34</td>
<td align="left">Carton of 100 unit dose</td>
</tr>
</tbody>
</table>
<p>Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=CAF64301-262C-45CA-ACD1-A9D6696C584E&amp;name=bextra-image04.jpg"></div>
<p>LAB-0266-7.0<br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BEXTRA 		
					</strong><br><span class="contentTableReg">valdecoxib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0025-1975</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>valdecoxib</strong> (valdecoxib) </td>
<td class="formItem"></td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromellose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">true</td>
<td class="formLabel">Symbol</td>
<td class="formItem">true</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0025-1975-31</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0025-1975-51</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0025-1975-34</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BEXTRA 		
					</strong><br><span class="contentTableReg">valdecoxib tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0025-1980</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>valdecoxib</strong> (valdecoxib) </td>
<td class="formItem"></td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>pregelatinized starch</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromellose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">true</td>
<td class="formLabel">Symbol</td>
<td class="formItem">true</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0025-1980-31</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0025-1980-51</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0025-1980-34</td>
<td class="formItem">100  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>G.D. Searle LLC</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>A9E4F68B-3EF6-FF3D-6351-5892324C336D</div>
<div>Set id: CAF64301-262C-45CA-ACD1-A9D6696C584E</div>
<div>Version: 1</div>
<div>Effective Time: 20060206</div>
</div>
</div> <div class="DistributorName">G.D. Searle LLC</div></p>
</body></html>
